WO2000023057A3 - Therapie visant a ameliorer la cognition - Google Patents

Therapie visant a ameliorer la cognition Download PDF

Info

Publication number
WO2000023057A3
WO2000023057A3 PCT/EP1999/007804 EP9907804W WO0023057A3 WO 2000023057 A3 WO2000023057 A3 WO 2000023057A3 EP 9907804 W EP9907804 W EP 9907804W WO 0023057 A3 WO0023057 A3 WO 0023057A3
Authority
WO
WIPO (PCT)
Prior art keywords
acetylcholinesterase inhibitor
atypical
antiphsychotic
combination
improving cognition
Prior art date
Application number
PCT/EP1999/007804
Other languages
English (en)
Other versions
WO2000023057A2 (fr
Inventor
Nijs Paul Leonce Irma De
Wim Louis Julien Parys
Original Assignee
Janssen Pharmaceutica Nv
Nijs Paul Leonce Irma De
Wim Louis Julien Parys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020017002286A priority Critical patent/KR20010072878A/ko
Priority to JP2000576832A priority patent/JP2002527469A/ja
Priority to BR9914419-0A priority patent/BR9914419A/pt
Priority to EP99952580A priority patent/EP1121131A2/fr
Priority to HU0103781A priority patent/HUP0103781A3/hu
Priority to SK459-2001A priority patent/SK4592001A3/sk
Priority to EEP200100136A priority patent/EE200100136A/xx
Priority to PL99348107A priority patent/PL348107A1/xx
Application filed by Janssen Pharmaceutica Nv, Nijs Paul Leonce Irma De, Wim Louis Julien Parys filed Critical Janssen Pharmaceutica Nv
Priority to IL14258899A priority patent/IL142588A0/xx
Priority to CA002345767A priority patent/CA2345767A1/fr
Priority to AU64727/99A priority patent/AU6472799A/en
Publication of WO2000023057A2 publication Critical patent/WO2000023057A2/fr
Publication of WO2000023057A3 publication Critical patent/WO2000023057A3/fr
Priority to BG105302A priority patent/BG105302A/xx
Priority to NO20011403A priority patent/NO20011403D0/no
Priority to HR20010262A priority patent/HRP20010262A2/hr
Priority to HK02100158.6A priority patent/HK1039745A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Cette invention a trait à des compositions pharmaceutiques renfermant un excipient et, comme premier ingrédient actif, un agent antipsychotique atypique (I), ainsi que, comme second ingrédient actif, un inhibiteur de l'acétylcholinestérase (II), chacun sous des quantités produisant un effet thérapeutique bénéfique chez des patients atteints de psychose, de la maladie d'Alzheimer ou de démences connexes. Cet effet thérapeutique bénéfique peut être un effet de synergie sur le fonctionnement cognitif de patients atteints de la maladie d'Alzheimer ou de démences connexes, être prophylactique, évitant une dégradation ultérieure de la cognition chez ces patients, ou encore atténuant les réactions indésirables dues à l'action sur l'un des ingrédients actifs des autres ingrédients actifs.
PCT/EP1999/007804 1998-10-16 1999-10-12 Therapie visant a ameliorer la cognition WO2000023057A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IL14258899A IL142588A0 (en) 1998-10-16 1999-10-12 Therapy for improving cognition
JP2000576832A JP2002527469A (ja) 1998-10-16 1999-10-12 認識を改良するための療法
CA002345767A CA2345767A1 (fr) 1998-10-16 1999-10-12 Therapie visant a ameliorer la cognition
HU0103781A HUP0103781A3 (en) 1998-10-16 1999-10-12 Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
SK459-2001A SK4592001A3 (en) 1998-10-16 1999-10-12 Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition
EEP200100136A EE200100136A (et) 1998-10-16 1999-10-12 Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon
PL99348107A PL348107A1 (en) 1998-10-16 1999-10-12 Therapy for improving cognition
KR1020017002286A KR20010072878A (ko) 1998-10-16 1999-10-12 인식을 개선하기 위한 아세틸콜린에스테라제 억제제와배합된 비정형 항정신병제
BR9914419-0A BR9914419A (pt) 1998-10-16 1999-10-12 Terapia para melhoria da percepção
EP99952580A EP1121131A2 (fr) 1998-10-16 1999-10-12 Therapie visant a ameliorer la cognition
AU64727/99A AU6472799A (en) 1998-10-16 1999-10-12 Therapy for improving cognition
BG105302A BG105302A (en) 1998-10-16 2001-03-01 Means for improving cognition
NO20011403A NO20011403D0 (no) 1998-10-16 2001-03-20 Terapi for Õ forbedre kongestion
HR20010262A HRP20010262A2 (en) 1998-10-16 2001-04-10 Therapy for improving cognition
HK02100158.6A HK1039745A1 (zh) 1998-10-16 2002-01-10 用於改善識別的非典型抗精神病藥和乙酰膽碱酯酶

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
EP98203454.8 1998-10-16

Publications (2)

Publication Number Publication Date
WO2000023057A2 WO2000023057A2 (fr) 2000-04-27
WO2000023057A3 true WO2000023057A3 (fr) 2000-07-27

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007804 WO2000023057A2 (fr) 1998-10-16 1999-10-12 Therapie visant a ameliorer la cognition

Country Status (20)

Country Link
EP (1) EP1121131A2 (fr)
JP (1) JP2002527469A (fr)
KR (1) KR20010072878A (fr)
CN (1) CN1367697A (fr)
AU (1) AU6472799A (fr)
BG (1) BG105302A (fr)
BR (1) BR9914419A (fr)
CA (1) CA2345767A1 (fr)
EE (1) EE200100136A (fr)
HK (1) HK1039745A1 (fr)
HR (1) HRP20010262A2 (fr)
HU (1) HUP0103781A3 (fr)
ID (1) ID28441A (fr)
IL (1) IL142588A0 (fr)
NO (1) NO20011403D0 (fr)
PL (1) PL348107A1 (fr)
SK (1) SK4592001A3 (fr)
TR (1) TR200101082T2 (fr)
WO (1) WO2000023057A2 (fr)
ZA (1) ZA200103081B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
JP5067998B2 (ja) 2001-10-30 2012-11-07 ノバルティス アーゲー イロペリドンおよび星形ポリマーのデポー製剤
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
AU2004325725A1 (en) * 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
CA2679446C (fr) 2007-03-01 2016-05-17 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
EP2533645B1 (fr) 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP2968220B1 (fr) 2013-03-15 2021-05-05 Agenebio, Inc. Procédés et compositions pour améliorer la fonction cognitive
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515301A2 (fr) * 1991-05-14 1992-11-25 Ernir Snorrason Amélioration des traitement avec benzodiazépines avec des inhibiteurs de choline esterase
EP0879596A2 (fr) * 1991-05-14 1998-11-25 Ernir Snorasson Utilisation d'inhibiteurs de cholinesterase contre les effets secondaires des benzodiazepines
WO1999007378A1 (fr) * 1997-08-11 1999-02-18 THE UNIVERSITY OF SOUTH FLORIDA A Corporation of the State of Florida Antagonistes de la nicotine destines a des troubles neuropsychiatriques sensibles a la nicotine
WO1999052519A2 (fr) * 1998-04-14 1999-10-21 The General Hospital Corporation Methodes de traitement de troubles neuropsychiatriques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515301A2 (fr) * 1991-05-14 1992-11-25 Ernir Snorrason Amélioration des traitement avec benzodiazépines avec des inhibiteurs de choline esterase
EP0879596A2 (fr) * 1991-05-14 1998-11-25 Ernir Snorasson Utilisation d'inhibiteurs de cholinesterase contre les effets secondaires des benzodiazepines
WO1999007378A1 (fr) * 1997-08-11 1999-02-18 THE UNIVERSITY OF SOUTH FLORIDA A Corporation of the State of Florida Antagonistes de la nicotine destines a des troubles neuropsychiatriques sensibles a la nicotine
WO1999052519A2 (fr) * 1998-04-14 1999-10-21 The General Hospital Corporation Methodes de traitement de troubles neuropsychiatriques

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ H.H. ET AL: "Donepezil for Huntington's disease.", MOVEMENT DISORDERS, (2000) 15/1 (173-176)., XP000892632 *
GALASKO D: "A CLINICAL APPROACH TO DEMENTIA WITH LEWY BODIES", THE NEUROLOGIST, vol. 5, no. 5, September 1999 (1999-09-01), pages 247 - 257, XP000878694 *
GEIZER M. ET AL: "Combination of risperidone and donepezil in Lewy body dementia", CAN. J. PSYCHIATRY, May 1998 (1998-05-01), pages 421 - 422, XP000892680 *
KELLY J S: "Alzheimer's disease: the tacrine legacy", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 20, no. 4, April 1999 (1999-04-01), pages 127 - 129, XP004172560, ISSN: 0165-6147 *
MAGNUSON T M ET AL: "Extrapyramidal side effects in a patient treated with risperidone plus donepezil [letter].", AMERICAN JOURNAL OF PSYCHIATRY, (1998 OCT) 155 (10) 1458-9., XP000892634 *
MAZUREK A. A.: "Treatment of Alzheimer's disease", N ENG J. MED, vol. 342, no. 11, 16 March 2000 (2000-03-16), pages 821 - 822, XP000901026 *
MELTZER, H. Y. (1) ET AL: "Atypical antipsychotic drugs (APD) but not typical APD increased extracellular acetylcholine (ACh-ext) levels in rat medial prefrontal cortex (mPFC) in the absence AChEsterase (AChE) inhibition.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1999) VOL. 25, NO. 1-2, PP. 452. MEETING INFO.: 29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 1 MIAMI BEACH, FLORIDA, USA OCTOBER 23-28, 1999 THE SOCIETY FOR NEUROSCIENCE., XP000892699 *
SIMONSON W.: "Promising agents for treating Alzheimer's disease.", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, (1 NOV 1998) 55/21 SUPPL. (S11-S16)., XP002134583 *
YAQUB B.A.: "New horizons in management of Alzheimer 's disease.", SAUDI MEDICAL JOURNAL, (1999) 20/9 (671-677)., XP000892838 *

Also Published As

Publication number Publication date
AU6472799A (en) 2000-05-08
NO20011403L (no) 2001-03-20
SK4592001A3 (en) 2001-12-03
HK1039745A1 (zh) 2002-05-10
EE200100136A (et) 2002-06-17
NO20011403D0 (no) 2001-03-20
HRP20010262A2 (en) 2002-06-30
ZA200103081B (en) 2002-07-12
WO2000023057A2 (fr) 2000-04-27
HUP0103781A2 (hu) 2002-03-28
TR200101082T2 (tr) 2001-09-21
BR9914419A (pt) 2001-06-26
ID28441A (id) 2001-05-24
BG105302A (en) 2001-11-30
HUP0103781A3 (en) 2003-09-29
PL348107A1 (en) 2002-05-06
EP1121131A2 (fr) 2001-08-08
IL142588A0 (en) 2002-03-10
JP2002527469A (ja) 2002-08-27
KR20010072878A (ko) 2001-07-31
CA2345767A1 (fr) 2000-04-27
CN1367697A (zh) 2002-09-04

Similar Documents

Publication Publication Date Title
WO2000023057A3 (fr) Therapie visant a ameliorer la cognition
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
CA2183972A1 (fr) Derives de l'oxazolidinone et compositions pharmaceutiques contenant ces derniers
BG106030A (en) Pharmaceutical composition
CA2317044A1 (fr) Medicament pour maladies neurodegeneratives
CA2356380A1 (fr) Effets immunosuppresseurs de derives de la pteridine
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
MXPA02000437A (es) Composicion para el tratamiento de trastornos de secrecion externa.
WO1999063977A3 (fr) Composition pharmaceutique destinee a traiter ou prevenir les troubles du sommeil
CA2214026A1 (fr) Compositions pharmaceutiques comprenant des inhibiteurs de la monoamine oxydase b
BR0012696A (pt) Composição oftálmica
MXPA02002452A (es) Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
EP2138175A3 (fr) Formulations comprenant du valsartan pour traiter le diabète ou la microalbuminurie
HUP0204049A3 (en) Compositions of combined active ingredients for treating glaucoma
IL159412A0 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
CA2282279A1 (fr) Atropisomeres de 3-heteroaryl-4(3h)-quinazolinones pour le traitement des troubles neurodegeneratifs et des troubles lies a un traumatisme du systeme nerveux central
TW354762B (en) Agent for prophylaxis or treatment of cataract
CA2192822A1 (fr) Utilisation d'agents immunosuppresseurs dans le traitement de la schizophrenie
PL324012A1 (en) N-hydroxyureas as antiinflammatory agents
EP0842663A4 (fr) Preparations ophtalmiques
WO2001005386A3 (fr) Composition pharmaceutique utile dans le traitement de bourdonnement d'oreilles et de surdite
EP1121932A4 (fr) Medicaments pour maladies oculaires
AU7941294A (en) Composition for the treatment or prevention of herpes
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812184.3

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 1999 64727

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999952580

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200100147

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 510015

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020017002278

Country of ref document: KR

Ref document number: 1020017002286

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1999 105302

Country of ref document: BG

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2345767

Country of ref document: CA

Ref document number: 2345767

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00354/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2001-1211

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 4592001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 09807160

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P20010262A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2000 576832

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/03081

Country of ref document: ZA

Ref document number: 200103081

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001/01082

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 142588

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/003835

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 64727/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: PV2001-1211

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017002286

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999952580

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1020017002278

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020017002278

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999952580

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017002286

Country of ref document: KR